Original Article

Increased Circulating Fetuin-A Levels in Patients with Atrial Fibrillation

Abstract

Background

Biomarkers related to the pathogenesis of atrial fibrillation (AF) have attracted the attention of experts. One of these recently studied biomarkers is Fetuin-A.

Objectives

This study aimed to evaluate the relationship between serum Fetuin-A levels and AF.

Methods

This study used the convenience sampling method, based on inclusion criteria and consent to participate in the study. The Shapiro-Wilk test was used to confirm the normal distribution of all continuous variables. Categorical variables were presented using absolute and relative frequencies. Both groups (48 patients with AF and 47 controls) were compared in terms of biochemical, hematological, and echocardiographic findings and Fetuin-A. the Chi-square or Fisher’s exact test were used to compare groups concerning categorical variables. Continuous variables were compared using the independent samples t-test. P<0.05 was considered statistically significant.

Results

Serum Fetuin-A values increased in AF patients when compared to the controls (544±49 μg/mL versus 484±46 μg/mL, p=0.001). Moreover, Fetuin-A level was independently associated with AF — AOR = 0.978, 95%; confidence interval (CI) 0.969-988, p 511.80 μg/mL with a sensitivity of 75% and a specificity of 73% — area under the curve (AUC) = 0.804, 95% CI = 0.715 – 0.892.

Conclusions

According to this study, there was a relationship between serum Fetuin-A levels and AF, regardless of conventional cardiovascular risk factors. Therefore, Fetuin-A may play a role in the pathophysiology of AF. Prospectively designed cohort studies are necessary to assess whether or not the results can be generalized for other populations.

Métricas

Visualizações 5
Métricas PlumX

Comentários

0 Comentário

Os comentários são moderados pela equipe editorial antes da publicação. As discussões devem ser baseadas em evidências e utilizar linguagem científica. Conflitos de interesse devem ser declarados.

Ainda não há comentários.

Enviar um comentário